title: Changes in aqueous cytokines after intravitreal triamcinolone versus bevacizumab for macular oedema in branch retinal vein occlusion.
abstract: OBJECTIVE
  To investigate the changes in the aqueous levels of various cytokines after intravitreal triamcinolone or bevacizumab for branch retinal vein occlusion (BRVO).
  
  
  METHODS
  Twenty-four eyes with macular oedema associated with BRVO and six eyes of six patients undergoing cataract surgery participated in this study. Each patient with BRVO randomly received an intravitreal injection of either 4 mg triamcinolone or 1.25 mg bevacizumab. Aqueous samples were obtained before and 4 weeks after the intravitreal injection in the BRVO group and before surgery in the control group. Aqueous concentrations of 16 cytokines were measured via multiplex bead assay.
  
  
  RESULTS
  Prior to the administration of the drugs, aqueous levels of interleukin (IL)-6, IL-8, IL-17 and vascular endothelial growth factor (VEGF) were significantly higher in the BRVO group than in the control group (p=0.044, p=0.013, p<0.001, and p=0.008, respectively). Between the control group and the BRVO group, no significant differences were noted between pre- and postinjection best-corrected visual acuity (p=0.60, p=0.54) and central foveal thickness (p=0.47, p=0.82). In the triamcinolone group, levels of IL-6, IL-17, IP-10, platelet-derived growth factor (PDGF)-AA and VEGF were reduced significantly (p=0.012, p<0.001, p<0.001, p=0.015, and p<0.001, respectively). But in bevacizumab group, only VEGF was significantly reduced (p<0.001). Between the IVTA group and the IVBe group, no significant differences in the changes in VEGF levels were noted (p=0.06).
  
  
  CONCLUSIONS
  Triamcinolone injection reduces plural inflammatory cytokines in BRVO, while bevacizumab has no influence on other cytokines as selective anti-VEGF therapy. No differences in the therapeutic effect were noted between an inhibition of plural inflammatory cytokines and an inhibition of VEGF only.
authors.affiliation: Department of Ophthalmology, Hongik Hospital, Seoul, KoreaDepartment of Ophthalmology, Gachon University Gil Hospital, Incheon, Korea.
authors.forename: Hee Jin
authors.initials: HJ
authors.lastname: Sohn
authors.forename: Dae Heon
authors.initials: DH
authors.lastname: Han
authors.forename: Dae Yeong
authors.initials: DY
authors.lastname: Lee
authors.forename: Dong Heun
authors.initials: DH
authors.lastname: Nam
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D001082:Aqueous Humor / Q000737:chemistry*; D000068258:Bevacizumab; D016207:Cytokines / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D012160:Retina / Q000473:pathology; D012170:Retinal Vein Occlusion / Q000150:complications* / Q000188:drug therapy / Q000378:metabolism; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014222:Triamcinolone Acetonide / Q000008:administration & dosage*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D016207:Cytokines; D005938:Glucocorticoids; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D014222:Triamcinolone Acetonide
keywords: bevacizumab; branch retinal vein occlusion; cytokines; macular oedema; triamcinolone; vascular endothelial growth factor